{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:35:31Z","timestamp":1793111731068,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007155","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N024591\/1"],"award-info":[{"award-number":["MR\/N024591\/1"]}],"id":[{"id":"10.13039\/501100007155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007155","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W015455\/1"],"award-info":[{"award-number":["MR\/W015455\/1"]}],"id":[{"id":"10.13039\/501100007155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010382","name":"European Society of Endocrinology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Prednisolone is widely prescribed but associated with marked interindividual variability in adverse effects. While 11\u03b2-hydroxysteroid dehydrogenase (11\u03b2-HSD) enzymes regulate glucocorticoid (GC) activation, the contribution of alternative clearance pathways remains unclear. We aimed to characterize prednisolone metabolism beyond 11\u03b2-HSD enzymes, define the roles of carbonyl reductase 1 (CBR-1) and AKR1C1, and assess the clinical relevance of specific metabolites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Post hoc targeted metabolomic analysis of a randomized, double-blind, placebo-controlled trial combined with mechanistic in vitro overexpression studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty healthy male volunteers from the TICSI trial (NCT03111810) and HEK293 cells overexpressing CBR-1 or AKR1C1 were studied. Participants received prednisolone (20\u2005mg daily for 1 week) with placebo or the selective 11\u03b2-HSD1 inhibitor AZD4017. In vitro, transfected HEK293 cells were treated with prednisolone or prednisone. Steroid metabolites were quantified by targeted LC\u2013MS\/MS, and associations with glucose disposal and osteocalcin were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>20\u03b2-reduced metabolites were major contributors to prednisolone clearance. In vitro, CBR-1 preferentially reduced prednisone, with 20\u03b2-dihydro-prednisone accounting for up to 78% of its clearance, whereas AKR1C1 had minimal impact. In vivo, 11\u03b2-HSD1 inhibition reduced prednisolone exposure without a compensatory rise in prednisone, with a relative increase in CBR-1\u2013mediated 20\u03b2-reduction. Higher circulating 20\u03b2-dihydro-prednisone at 4\u2005h independently predicted improved glucose disposal and higher osteocalcin levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CBR-1 is a key determinant of prednisolone and prednisone clearance in humans and is associated with clinically relevant metabolic and skeletal outcomes. Circulating 20\u03b2-dihydro-prednisone may serve as an informative biomarker of GC exposure and adverse effect risk, supporting metabolite-guided approaches to GC therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvag193","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:49:40Z","timestamp":1791978580000},"page":"646-657","source":"Crossref","is-referenced-by-count":0,"title":["Carbonyl reductase 1 regulates prednisolone clearance and modifies its adverse effect profile"],"prefix":"10.1093","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-5735","authenticated-orcid":false,"given":"Riccardo","family":"Pofi","sequence":"first","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital , Oxford OX37LJ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Potter","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital , Oxford OX37LJ ,","place":["United Kingdom"]},{"name":"Department of Biological and Medical Sciences, Oxford Brookes University , Oxford OX30BP ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Coll","sequence":"additional","affiliation":[{"name":"Doping Control Research Group, Catalonian Antidoping Laboratory, Hospital del Mar Research Institute , Barcelona 08003 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-6328","authenticated-orcid":false,"given":"Nantia","family":"Othonos","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital , Oxford OX37LJ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish","family":"Miller","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital , Oxford OX37LJ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"White","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital , Oxford OX37LJ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Haylock","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital , Oxford OX37LJ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Monfort","sequence":"additional","affiliation":[{"name":"Doping Control Research Group, Catalonian Antidoping Laboratory, Hospital del Mar Research Institute , Barcelona 08003 ,","place":["Spain"]},{"name":"Department of Experimental and Health Sciences, Universitat Pompeu Fabra , Barcelona 08003 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ventura","sequence":"additional","affiliation":[{"name":"Doping Control Research Group, Catalonian Antidoping Laboratory, Hospital del Mar Research Institute , Barcelona 08003 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3170-8533","authenticated-orcid":false,"given":"Jeremy W","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital , Oxford OX37LJ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"3","key":"2026102709521428900_lvag193-B1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1530\/EJE-19-0305","article-title":"Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark","volume":"181","author":"Laugesen","year":"2019","journal-title":"Eur J Endocrinol."},{"key":"2026102709521428900_lvag193-B2"},{"issue":"6","key":"2026102709521428900_lvag193-B3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1210\/endrev\/bnad016","article-title":"Treating the side effects of exogenous glucocorticoids; can we separate the good from the bad?","volume":"44","author":"Pofi","year":"2023","journal-title":"Endocr Rev."},{"issue":"6","key":"2026102709521428900_lvag193-B4","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1210\/clinem\/dgag123","article-title":"Mortality risk and causes of death in exogenous Cushing's syndrome: a systematic review and meta-analysis","volume":"111","author":"Limumpornpetch","year":"2026","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2026102709521428900_lvag193-B5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.4158\/EP.12.4.358","article-title":"Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients","volume":"12","author":"Donihi","year":"2006","journal-title":"Endocr Pract."},{"issue":"2","key":"2026102709521428900_lvag193-B6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/bja\/ael111","article-title":"Blood glucose concentration profile after 10 mg dexamethasone in non-diabetic and type 2 diabetic patients undergoing abdominal surgery","volume":"97","author":"Hans","year":"2006","journal-title":"Br J Anaesth."},{"issue":"2","key":"2026102709521428900_lvag193-B7","doi-asserted-by":"publisher","first-page":"c54","DOI":"10.1159\/000097598","article-title":"Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases","volume":"105","author":"Uzu","year":"2007","journal-title":"Nephron Clin Pract."},{"issue":"9","key":"2026102709521428900_lvag193-B8","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s40618-025-02637-x","article-title":"Dose-dependent and tissue-specific adverse effects of exogenous glucocorticoids: insights for optimizing clinical practice","volume":"48","author":"Pofi","year":"2025","journal-title":"J Endocrinol Invest."},{"issue":"3","key":"2026102709521428900_lvag193-B9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/jms.3571","article-title":"Detection and characterization of prednisolone metabolites in human urine by LC-MS\/MS","volume":"50","author":"Matabosch","year":"2015","journal-title":"J Mass Spectrom."},{"issue":"4","key":"2026102709521428900_lvag193-B10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1210\/er.2012-1050","article-title":"11\u03b2-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects","volume":"34","author":"Gathercole","year":"2013","journal-title":"Endocr Rev."},{"issue":"1","key":"2026102709521428900_lvag193-B11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1210\/jcem.87.1.8189","article-title":"Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion","volume":"87","author":"Tomlinson","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2026102709521428900_lvag193-B12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1507\/endocrj.K08E-008","article-title":"A case of cortisol producing adrenal adenoma without phenotype of Cushing's syndrome due to impaired 11beta-hydroxysteroid dehydrogenase 1 activity","volume":"55","author":"Arai","year":"2008","journal-title":"Endocr J."},{"issue":"9","key":"2026102709521428900_lvag193-B13","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae158","article-title":"Impaired 11\u03b2-HSD1 activity in a male patient with Cushing disease resulting in lack of the full cushingoid phenotype","volume":"2","author":"Weber","year":"2024","journal-title":"JCEM Case Rep."},{"issue":"10","key":"2026102709521428900_lvag193-B14","doi-asserted-by":"publisher","first-page":"e3865","DOI":"10.1210\/clinem\/dgab450","article-title":"An open-label phase I\/IIa clinical trial of 11\u03b2-HSD1 inhibitor for Cushing's syndrome and autonomous cortisol secretion","volume":"106","author":"Oda","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2026102709521428900_lvag193-B15","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41467-023-36541-w","article-title":"11\u03b2-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial","volume":"14","author":"Othonos","year":"2023","journal-title":"Nat Commun."},{"issue":"23","key":"2026102709521428900_lvag193-B16","doi-asserted-by":"publisher","first-page":"6841","DOI":"10.1007\/s00216-022-04249-3","article-title":"Quantification of cortisol and its metabolites in human urine by LC-MSn: applications in clinical diagnosis and anti-doping control","volume":"414","author":"Arioli","year":"2022","journal-title":"Anal Bioanal Chem."},{"issue":"1","key":"2026102709521428900_lvag193-B17","doi-asserted-by":"publisher","first-page":"10633","DOI":"10.1038\/s41598-017-10410-1","article-title":"Carbonyl reductase 1 catalyzes 20\u03b2-reduction of glucocorticoids, modulating receptor activation and metabolic complications of obesity","volume":"7","author":"Morgan","year":"2017","journal-title":"Sci Rep."},{"issue":"2","key":"2026102709521428900_lvag193-B18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/clinchem\/29.2.385","article-title":"Increased urinary excretion of free 20 alpha- and 20 beta-dihydrocortisol in a hypercortisolemic but hypocortisoluric patient with Cushing's disease","volume":"29","author":"Schoneshofer","year":"1983","journal-title":"Clin Chem."},{"issue":"3","key":"2026102709521428900_lvag193-B19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/dta.2966","article-title":"Elimination profiles of prednisone and prednisolone after different administration routes: evaluation of the reporting level and washout periods to ensure safe therapeutic administrations","volume":"13","author":"Coll","year":"2021","journal-title":"Drug Test Anal."},{"issue":"2","key":"2026102709521428900_lvag193-B20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/JOE-19-0473","article-title":"Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo","volume":"245","author":"Nikolaou","year":"2020","journal-title":"J Endocrinol."},{"issue":"6","key":"2026102709521428900_lvag193-B21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1210\/endrev\/bnae016","article-title":"Current challenges and future directions in the assessment of glucocorticoid status","volume":"45","author":"Clarke","year":"2024","journal-title":"Endocr Rev."},{"issue":"5","key":"2026102709521428900_lvag193-B22","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1210\/clinem\/dgz277","article-title":"GDF15 is elevated in conditions of glucocorticoid deficiency and is modulated by glucocorticoid replacement","volume":"105","author":"Melvin","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"2026102709521428900_lvag193-B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2021.100256","article-title":"Evaluation of FKBP5 as a cortisol activity biomarker in patients with ACTH-dependent Cushing syndrome","volume":"24","author":"Bancos","year":"2021","journal-title":"J Clin Transl Endocrinol."},{"key":"2026102709521428900_lvag193-B24","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.62236.sa2","article-title":"Author response: identification of human glucocorticoid response markers using integrated multi-omic analysis from a randomized crossover trial","volume":"10","author":"Chantzichristos","year":"2021","journal-title":"Elife"},{"key":"2026102709521428900_lvag193-B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2019.105439","article-title":"Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: a comprehensive review","volume":"194","author":"Schiffer","year":"2019","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"2","key":"2026102709521428900_lvag193-B26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/0378-4347(91)80040-J","article-title":"Liquid chromatographic analysis of prednisolone, prednisone and their 20-reduced metabolites in perfusion media","volume":"563","author":"Cannell","year":"1991","journal-title":"J Chromatogr."},{"issue":"4","key":"2026102709521428900_lvag193-B27","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1210\/jcem-55-4-762","article-title":"Prednisolone clearance at steady state in man","volume":"55","author":"Legler","year":"1982","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2026102709521428900_lvag193-B28","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1080\/17425255.2017.1356820","article-title":"The role of carbonyl reductase 1 in drug discovery and development","volume":"13","author":"Shi","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"2026102709521428900_lvag193-B29","doi-asserted-by":"publisher","first-page":"101225","DOI":"10.1016\/j.molmet.2021.101225","article-title":"Carbonyl reductase 1 amplifies glucocorticoid action in adipose tissue and impairs glucose tolerance in lean mice","volume":"48","author":"Bell","year":"2021","journal-title":"Mol Metab."},{"issue":"1","key":"2026102709521428900_lvag193-B30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.pharmtox.47.120505.105316","article-title":"Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology","volume":"47","author":"Oppermann","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol."}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvag193\/71957472\/lvag193.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/4\/646\/71957472\/lvag193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/4\/646\/71957472\/lvag193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:52:21Z","timestamp":1793109141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/195\/4\/646\/8916841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag193","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10]]}}}